Lyell Immunopharma Stock
Lyell Immunopharma, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Lynn Seely
- Employees
- 161
- Market cap
- $199 M
- IPO
- 17/06/2021
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell…
Lyell Immunopharma stock: price history
1D
-0.9%
1W
-6.8%
1M
-24.7%
6M
-66.2%
YTD
-73.6%
1Y
-52.2%
2Y
-67.5%
5Y
-96.9%
10Y
–
Next earnings date
Next earnings date
10/11/2026 (in 24 days)
Volatility around earnings
~11% stronger price swings than usual
Ask the agents about Lyell Immunopharma
Analyst assessment of Lyell Immunopharma
PRICE TARGET LOW
US$34.00
CONSENSUS
US$42.67
MEDIAN
US$45.00
PRICE TARGET HIGH
US$49.00
0
STRONG BUY
3
BUY
3
HOLD
1
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 11/09/2026
Lyell Immunopharma stock metrics
P/E
-0.51
P/B
0.81
EV/EBITDA
-0.68
RETURN ON EQUITY
-19.1%
NET MARGIN
-1,118,875.0%
DEBT/EQUITY
0.16
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
59.7%
FLOAT SHARES
14,618,907
AVG. DAILY VOLUME (30D)
162,315
Insider transactions (SEC)
Aguirre Jarrad Mattieu
Shook David
Hill Stephen J.
Seely Lynn
Lee Gary K.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Lyell Immunopharma stock
What does Lyell Immunopharma do?
Lyell Immunopharma, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Lynn Seely, the company employs around 161 people.
The IPO was on 17/06/2021; the stock trades on NASDAQ under the ticker LYEL.
What do analysts say about Lyell Immunopharma stock?
7 analysts rate the stock, the consensus is Buy (as of 11/09/2026).
The average price target is US$42.67, ranging from US$34.00 to US$49.00, with a median of US$45.00.
This is an external assessment, not a statement by Market Jury.
When does Lyell Immunopharma report next?
The next earnings date is 10/11/2026.
Around past earnings, price swings were roughly 11% stronger than usual.
Does Lyell Immunopharma pay a dividend?
No, Lyell Immunopharma currently does not pay a dividend.
Which stocks are comparable to Lyell Immunopharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Lyell Immunopharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess Lyell Immunopharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.